In the first part of this study, agar dilution MICs were used to test the activities of trovafloxacin, ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin, clinafloxacin, ceftazidime, and imipenem against 458 gramnegative nonfermenters. The overall respective MICs at which 50% of isolates are inhibited (MIC 50 s) and MIC 90 s were as follows: trovafloxacin, 1.0 and 16.0 g/ml; ciprofloxacin, 2.0 and 16.0 g/ml; ofloxacin, 2.0 and 32.0 g/ml; levofloxacin, 1.0 and 16.0 g/ml; sparfloxacin, 1.0 and 16.0 g/ml; clinafloxacin, 0.5 and 4.0 g/ml; ceftazidime, 8.0 and 128.0 g/ml; imipenem, 2.0 and 256.0 g/ml. Clinafloxacin was the most active of all the quinolones tested. The MIC 90 s of trovafloxacin were <4.0 g/ml for Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Flavobacterium odoratum, and Chryseobacterium meningosepticum; trovafloxacin MIC 90 s were <2.0 g/ml for Moraxella spp., Pseudomonas stutzeri, and Chryseobacterium indologenes-C. gleum. Of the other quinolones tested, the MICs of sparfloxacin and levofloxacin were lower than those of ciprofloxacin and ofloxacin. High ceftazidime MICs (>32.0 g/ml) were observed for all nonfermentative species tested. Although for the majority of strains tested imipenem MICs were <8.0 g/ml, high imipenem MICs were observed for many species, especially S. maltophilia, Burkholderia cepacia, F. odoratum, and Chryseobacterium meningosepticum. Gram-negative nonfermentative rods are increasingly implicated as causative agents in human disease. The organisms are acquired as a result of contact with environmental strains as well as through nosocomial transmission (1-4, 18, 21, 38, 42, 43). Although Pseudomonas aeruginosa is the nonfermenter most commonly encountered clinically, other gram-negative nonfermentative rods are being recovered from debilitated or immunosuppressed hosts with increasing frequency (1-4, 18, 21, 38, 42, 43). The antimicrobial susceptibility patterns of the nonfermenters differ from those of the members of the family Enterobacteriaceae in many respects, and among the nonfermenters, many groups have susceptibility spectra which differ from the spectrum for P. aeruginosa. The unpredictability and breadth of drug resistance of many nonfermenters and the development of new antimicrobial agents with wider spectra of activity against these organisms make in vitro susceptibility testing a major component of rational therapy (1-4, 18, 21, 38, 42, 43).
Gram-negative nonfermentative rods are increasingly implicated as causative agents in human disease. The organisms are acquired as a result of contact with environmental strains as well as through nosocomial transmission (1-4, 18, 21, 38, 42, 43) . Although Pseudomonas aeruginosa is the nonfermenter most commonly encountered clinically, other gram-negative nonfermentative rods are being recovered from debilitated or immunosuppressed hosts with increasing frequency (1-4, 18, 21, 38, 42, 43) . The antimicrobial susceptibility patterns of the nonfermenters differ from those of the members of the family Enterobacteriaceae in many respects, and among the nonfermenters, many groups have susceptibility spectra which differ from the spectrum for P. aeruginosa. The unpredictability and breadth of drug resistance of many nonfermenters and the development of new antimicrobial agents with wider spectra of activity against these organisms make in vitro susceptibility testing a major component of rational therapy (1-4, 18, 21, 38, 42, 43) .
Trovafloxacin is a new broad-spectrum naphthyridone with activity against a wide variety of gram-positive and -negative aerobic and anaerobic bacteria (10, 20, 37) . This study was divided into two parts. (i) We first tested the activity of trovafloxacin and compared it with the activities of other quinolone and nonquinolone agents against 458 nonfermenters by the agar dilution method. Five strains were also examined by the time-kill method. (ii) In the second part of the study, we tested whether the activity of the combination of trovafloxacin with ceftazidime, amikacin, and imipenem was synergistic against 286 nonfermenters by the checkerboard titration method and 20 strains by the time-kill method.
MATERIALS AND METHODS
Bacteria. The organisms tested in this study were all clinical isolates collected within the past 7 years from Hershey Medical Center, University Hospitals of Cleveland, the Cleveland Clinic, and Hôpital St. Louis, Paris, France. Data for 50% of strains, especially strains of Stenotrophomonas maltophilia, Burkholderia cepacia, and Acinetobacter genospecies, were not included in a previous report (38) from our laboratory; the P. aeruginosa strains tested in the present study were also not included in that study (38) . Strains were all identified by conventional methods (18, 42) . For the purposes of this study, Pseudomonas fluorescens and Pseudomonas putida strains and Chryseobacterium indologenes-C. gleum were not differentiated. Because of the complicated nature of current taxonomy (42) , Acinetobacter strains were divided into Acinetobacter baumannii strains and nonAcinetobacter baumannii strains by gas-liquid chromatographic analysis (MIDI, Newark, Del.). Organisms were frozen at Ϫ70°C in double-strength litmus milk prior to testing. Purity was checked throughout the study by Gram staining and examination of colonial morphology.
Agar dilution MIC determination. MICs for 458 strains were determined by the agar dilution method recommended by the National Committee for Clinical Laboratory Standards (NCCLS) (27) by using cation-adjusted Mueller-Hinton 
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agar (BBL Microbiology Systems, Cockeysville, Md.). When testing Moraxella spp., 5% sheep blood was added to the medium. Suspensions with a turbidity equivalent to that of a 0.5 McFarland standard were prepared by suspending growth from blood agar plates in 2 ml of Mueller-Hinton broth (BBL). Suspensions were further diluted 1:10 to obtain a final inoculum of 10 4 CFU/spot. Plates were inoculated with a Steers replicator and were incubated overnight in ambient air at 37°C. Standard quality control strains were included in each run. It is noteworthy that standardized methods have not been approved by NCCLS for most of the organisms tested in the current study. Although organisms do grow by the methods outlined by NCCLS, interpretive breakpoints have only been established for P. aeruginosa and, perhaps, Acinetobacter genospecies.
Broth MIC determination. For the five strains tested by the time-kill method, MICs were determined by the microdilution method recommended by NCCLS (27) by using cation-adjusted Mueller-Hinton broth (Difco Laboratories, Detroit, Mich.). Suspensions with a turbidity equivalent to that of a 0.5 McFarland standard were prepared by suspending growth from blood agar plates in 2 ml of sterile saline. Suspensions were further diluted 1:10 to obtain a final inoculum of 5 ϫ 10 5 CFU/well. Trays were incubated overnight in ambient air at 37°C. Standard quality control strains were included in each run.
Time-kill assays. For time-kill assays with the five strains mentioned above, glass tubes containing 5 ml of cation-adjusted Mueller-Hinton broth (Difco) with doubling antibiotic concentrations were inoculated with 5 ϫ 10 5 to 5 ϫ 10 6 CFU/ml and were incubated at 35°C in a shaking water bath. Antibiotic concentrations were chosen to comprise 3 doubling dilutions above and 4 doubling dilutions below the agar dilution MIC. The bacterial inoculum was prepared by diluting suspensions harvested from plates (the medium was as described above) in the same medium. The dilutions required to obtain the correct inoculum (5 ϫ 10 5 to 5 ϫ 10 6 CFU/ml) were determined by prior viability studies with each strain (29, 38) .
To inoculate each tube of serially diluted antibiotic, 50 l of diluted inoculum was delivered beneath the surface of the broth with a pipette. The tubes were then vortexed and their contents were plated for viability counts (0 h). Only tubes containing an initial inoculum within the range of 5 ϫ 10 5 to 5 ϫ 10 6 CFU/ml were acceptable.
Viability counts of antibiotic-containing suspensions were performed at 0, 6, 12, and 24 h by plating 0.1-ml aliquots of 10-fold dilutions from each tube in sterile Mueller-Hinton broth onto Trypticase soy agar-5% sheep blood agar plates (BBL). The plates used to recover organisms were incubated for up to 48 h. Colony counts were performed for plates yielding 30 to 300 colonies. The lower limit of sensitivity of colony counts was 300 CFU/ml (29, 38) .
Time-kill assay results were analyzed by determining the number of strains which yielded a changes in the log 10 CFU per milliliter of Ϫ1, Ϫ2, and Ϫ3 compared to the counts at time zero for all seven compounds at all five time periods. Antimicrobial agents were considered bactericidal at the lowest concentration that reduced the original inoculum by Ͼ3 log 10 CFU/ml (99.9%) at each of the respective time periods and bacteriostatic if the inoculum was reduced by 0 to 3 log 10 CFU/ml. With the inocula and viability count thresholds used in these studies, 99.9% killing, when present, could be readily detected. The problem of bacterial carryover was addressed as described previously (29, 38) .
Checkerboard synergy testing. Checkerboard synergy testing was performed for 286 strains in microtiter trays with cation-supplemented Mueller-Hinton broth (Difco) (4, 5, 14) . By using two microdilution trays, trovafloxacin was tested at 14 concentrations (0.004 to 32.0 g/ml), ceftazidime and amikacin were each tested at 11 concentrations (0.06 to 64.0 g/ml), and imipenem was tested at 11 concentrations (0.016 to 16.0 g/ml). The trays were prepared with a 96-channel dispenser and were stored at Ϫ70°C until use. Trovafloxacin was dispensed alone in the first row and was combined with ceftazidime, amikacin, or imipenem in the remaining rows. Ceftazidime, amikacin, and imipenem were also dispensed alone in the first column. Inocula were prepared by suspending growth from blood agar plates in sterile saline to a density equivalent to that of a 0. Time-kill determinations. Twenty strains were tested by the time-kill method as described above. All four compounds were tested alone, and trovafloxacin was tested in combination with each of ceftazidime, amikacin, and imipenem. In each case, concentrations four times above and four times below the MICs were tested. Viability counts were performed at 0, 6, 12, and 24 h. Drug carryover was addressed as described previously (29, 38) . Synergy was defined as a Ն2 log 10 decrease in viable count with the combination at 24 h compared to the viable count with the more active of the two compounds alone (4, 5, 9) .
RESULTS
The results of agar dilution MIC testing of 458 strains are presented in Table 1 . Different nonfermentative species differed in their susceptibilities to quinolone and nonquinolone agents. The overall respective MICs at which 50% of strains are inhibited (MIC 50 s) and MIC 90 s were as follows: trovafloxacin, 1.0 and 16.0 g/ml; ciprofloxacin, 2.0 and 16.0 g/ml; ofloxacin, 2.0 and 32.0 g/ml; levofloxacin, 1.0 and 16.0 g/ml; sparfloxacin, 1.0 and 16.0 g/ml; clinafloxacin, 0.5 and 4.0 g/ml; ceftazidime, 8.0 and 128.0 g/ml; and imipenem, 2.0 and 256.0 g/ml.
In general, clinafloxacin was the most active of all the quinolones tested. Trovafloxacin MIC 90 s were Յ4.0 g/ml for P. aeruginosa, S. maltophilia, Flavobacterium odoratum, and Chryseobacterium meningosepticum. For Moraxella spp., Pseudomonas stutzeri, and Chryseobacterium indologenes-C. gleum, trovafloxacin MICs were Յ2.0 g/ml. A bimodal distribution of trovafloxacin MICs for A. baumannii species was observed, b Alcaligenes xylosoxidans subsp. denitrificans (n ϭ 13) and Alcaligenes xylosoxidans subsp. xylosoxidans (n ϭ 27).
c Moraxella osloensis (n ϭ 6), Moraxella phenylpyruvica (n ϭ 1), Moraxella nonliquefaciens (n ϭ 1), and Oligella urethralis (n ϭ 1).
d Shewanella putrefaciens (n ϭ 6), Sphingomonas paucimobilis (n ϭ 5), Pseudomonas alcaligenes (n ϭ 3), Brevundimonas vesicularis (n ϭ 4), Burkholderia pickettii (n ϭ 2), Flavimonas oryzihabitans (n ϭ 4), Chromobacterium violaceum (n ϭ 2), Methylobacterium spp. (n ϭ 2), Comamonas acidovorans (n ϭ 3), Sphingobacterium multivorum (n ϭ 6), Agrobacterium radiobacter (n ϭ 1), Pseudomonas mendocina (n ϭ 2), Ochrobactrum anthropi (n ϭ 1), Pseudomonas pseudoalcaligenes (n ϭ 1), Comamonas testosteroni (n ϭ 1), Weeksella zoohelcum (n ϭ 1), and CDC group IVe (n ϭ 1).
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on October 19, 2017 by guest http://aac.asm.org/ with strains being either very susceptible (Յ0.5 g/ml) or very resistant (Ն8.0 g/ml). For all non-A. baumannii strains tested, trovafloxacin MICs were Յ0.5 g/ml. Similar results were obtained with all quinolones tested. The MICs of ceftazidime (Յ16.0 g/ml) and imipenem (Յ2.0 g/ml) were also lower for non-A. baumannii strains than for A. baumannii strains. The other quinolones tested showed similar susceptibility patterns for the different nonfermentative groups, with the MICs of sparfloxacin and levofloxacin being lower than those of ciprofloxacin and ofloxacin. High ceftazidime MIC 90 s (Ն32.0 g/ml) were observed for all nonfermentative species tested. Although for the majority of strains tested imipenem MICs were Յ8.0 g/ml, high imipenem MICs were observed for many species, especially S. maltophilia, B. cepacia, F. odoratum, and C. meningosepticum. For Alcaligenes xylosoxidans strains, the MICs of all compounds were generally a few dilutions lower than those for Alcaligenes faecalis-A. odorans strains. The broth dilution MICs for strains tested by the time-kill method are presented in Table 2 . All strains except B. cepacia were inhibited by trovafloxacin and all quinolones (MICs, Յ4.0 g/ml). Ceftazidime inhibited P. aeruginosa, S. maltophilia, and C. meningosepticum at Յ4.0 g/ml, while imipenem was active against P. aeruginosa, A. baumannii, and C. meningosepticum at Յ2.0 g/ml.
In time-kill studies, imipenem, trovafloxacin, and all quinolones except sparfloxacin at eight times the MIC yielded 99.9% killing for all five strains after 24 h; sparfloxacin yielded 99.9% killing for four of five strains after 24 h. Ceftazidime at eight times the MIC was bactericidal for only two of five strains after 24 h. Regrowth was observed with quinolones after 6 h for P. aeruginosa and S. maltophilia.
Microdilution test results for the 286 strains used in the checkerboard titrations are presented in Time-kill test results for synergy are listed in Table 5 . For most strains for which FIC indices indicated additivity or indifference by the checkerboard test, the FIC indices by the time-kill experiments indicated synergy. Synergy was particularly evident for S. maltophilia strains. In only one strain of Brevundimonas vesicularis (trovafloxacin-amikacin) did checkerboard titration yield synergy but time-kill study results were additive or indifferent.
DISCUSSION
Trovafloxacin is a broad-spectrum naphthyridone with activity against gram-positive aerobic cocci and rods, members of the family Enterobacteriaceae, and gram-positive and -negative anaerobes (10, 18, 37) . In the current study, trovafloxacin MICs were low (generally Յ4.0 g/ml) for P. aeruginosa, S. maltophilia, Pseudomonas stutzeri, Moraxella spp., and Flavobacterium and Chryseobacterium spp. In line with previous findings (34), A. baumannii strains were more resistant than non-A. baumannii strains to quinolone and nonquinolone agents. Fass and coworkers (16) , in a study of 308 gram-negative nonfermenters, found trovafloxacin to be considerably more active than ciprofloxacin and ofloxacin against S. maltophilia, A. baumannii, and several less common species. However, trovafloxacin MICs for P. aeruginosa and S. maltophilia were higher than those reported here; strain differences may account for this discrepancy.
Checkerboard titrations revealed significant synergism between trovafloxacin and ceftazidime against S. maltophilia. No c Moraxella osloensis (n ϭ 8) and Moraxella nonliquefaciens (n ϭ 2). d Sphingomonas paucimobilis (n ϭ 2), Pseudomonas pseudoalcaligenes (n ϭ 5), Pseudomonas stutzeri (n ϭ 5), Pseudomonas mendocina (n ϭ 3), Burkholderia pickettii (n ϭ 1), Ochrobactrum anthropi (n ϭ 1), Comamonas acidovorans (n ϭ 1), Comamonas testosteroni (n ϭ 1), Brevundimonas diminuta (n ϭ 3), Brevundimonas vesicularis (n ϭ 3), Sphingobacterium multivorum (n ϭ 4), Flavimonas oryzihabitans (n ϭ 2), Weeksella virosa (n ϭ 1), and CDC IV C-2 (n ϭ 1). FIC indices indicating antagonism were observed for any of the combinations. Results of synergy testing revealed discrepant results between the checkerboard titration and time-kill experiments, with time-kill experiments yielding the most favorable results. This phenomenon has previously been observed for Streptococcus pneumoniae with ␤-lactams and glycopeptides (5), Acinetobacter genospecies with quinolones and amikacin (4), P. aeruginosa with ␤-lactams and an aminoglycoside (9) , and members of the family Enterobacteriaceae with various drug combinations (9) . The problem is further complicated by a lack of standardization of the two techniques to determine synergy (14) . Although synergy was found for all strains except A. xylosoxidans by the time-kill method, the results should be interpreted carefully, and the levels of the respective compounds achievable in human serum should also be considered. For example, a combination of trovafloxacin plus imipenem is not indicated for S. maltophilia, owing to inherent imipenem resistance in this species. Taken together, however, results of the checkerboard titration and time-kill method indicate clear synergy between trovafloxacin and ceftazidime for S. maltophilia strains. Given the tendency of S. maltophilia to develop resistance on exposure to ceftazidime, the clinical significance of the synergy observed with trovafloxacin is unknown. An animal model is being developed to investigate this phenomenon further.
Of the individual strains tested, the S. maltophilia strains tested revealed susceptibility and time-kill patterns typical of this strain: low quinolone MICs for the strains, especially those of trovafloxacin and sparfloxacin, higher ceftazidime MICs for the strains, and resistance to imipenem. Time-kill study results showed regrowth after 24 h. Bimodal susceptibility distributions were seen in Acinetobacter genospecies for all quinolones tested. Resistance in B. cepacia and Alcaligenes spp. has been described before, and the susceptibility patterns of Flavobacterium and Chryseobacterium spp. as well as those of less commonly occurring nonfermentative species are also in line with those in previous reports (1-4, 6-8, 11, 13, 15, 17, 19, 21, 22-26, 28, 30-36, 38-41, 43 ).
Among all quinolones tested, the MICs of clinafloxacin were the lowest for all strains, in agreement with previous studies (44) . Of the other quinolones tested, sparfloxacin and levofloxacin had lower MICs, similar to those of trovafloxacin, for a bacterial population substantially different from that studied previously in our laboratory (38) .
Widespread resistance to ceftazidime, together with significantly increased bactericidal compared to bacteriostatic values for most strains tested, limits the use of this compound for the treatment of infections caused by nonfermenters. In the current study, ceftazidime MICs were Ն32.0 g/ml for 17 of 89 (19.1%) P. aeruginosa strains. Widespread imipenem resistance in species other than those with known inherent resistance (S. maltophilia, flavobacteria, and chryseobacteria) mandates susceptibility testing with this compound in all cases of serious infections caused by gram-negative nonfermenters. Different susceptibilities in different species mandates susceptibility testing of all clinically significant gram-negative nonfermenters. The problem is complicated by the fact that no approved breakpoints are available for nonfermenters other than P. aeruginosa and perhaps Acinetobacter.
In two previous studies, synergy between each of three quinolones (levofloxacin, ofloxacin, and ciprofloxacin) and amikacin has been demonstrated for Acinetobacter genospecies for which quinolone MICs were Յ2.0 g/ml by time-kill (but not checkerboard) testing (4, 12) . The current study indicates a possible place for combination therapy with trovafloxacin and other agents for selected nonfermentative strains and suggests that other quinolones may be combined with amikacin, ceftazidime, or imipenem in selected cases. The latter hypothesis requires laboratory testing for confirmation.
Clinical studies are required to test the relevance of the increased activities of trovafloxacin (with and without other However, these will be difficult to achieve, given the infrequency with which many of these organisms can be definitively implicated in human infection versus colonization. Animal models may help in this regard and need to be developed. This study has highlighted the widespread resistance of all nonfermentative strains tested to quinolones and nonquinolones and demonstrates the need for the development of agents with activities against this group of organisms.
